Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi

Ozer, Zeynep; SERT, MEDIHA

doi:10.5543/khd.2019.88700

Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi

Mediha SERT, (Girilmemişş)

Zeynep ÖZER (Girilmemişş)

Kardiyovasküler Hemşirelik Dergisi

5 0

Yıl: 2019 Cilt: 10 Sayı: 21 Sayfa Aralığı: 25 - 32 Metin Dili: Türkçe DOI: 10.5543/khd.2019.88700 İndeks Tarihi: 17-11-2020

Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi

Öz:

Son yıllarda yapılan çalışmalar, intestinal mikrobiyotanın insan sağlığı ve hastalığı üzerine etkili olması, kardiyovaskülerhastalıklar (KVH) dahil olmak üzere birçok hastalıkla ilişkili bulunması nedeniyle, intestinal mikrobiyotanın bireyler üzerine olan etkisine odaklanmıştır. KVH, insidansı oldukça yüksek olan ve ölümle sonuçlanabilen önemli bir hastalıkgrubudur. Dünyadaki ölümlerin %31’i KVH nedeniyle gerçekleşmiş olup, bu değerin on yıl sonra %41’e ulaşacağıöngörülmektedir. Yapılan çalışmalarda, immün sistem, enflamasyon süreci, endotel hasar ve vasküler değişikliklerinintestinal mikrobiyotayı etkilediği ve bunun sonucunda birçok KVH ve metabolik hastalıkların geliştiği bildirilmiştir.Bu durum intestinal mikrobiyotanın incelenmesi ve düzenlenmesi ile hastalıkların tespit edilebileceği ve önlenmesinin mümkün olabileceği düşüncelerini geliştirmiştir. Bireylerin hastalıklardan korunması ve sağlığın geliştirilereksürdürülmesinde en büyük rol hemşirelere aittir. Hemşireler güncel yaklaşımlara ilişkin bilgilerini artırmalı, mikrobiktoplulukların temel yapı ve işlevlerini bilmeli ve geliştirdiği bilgi ve becerilerini bakımlarına yansıtabilmelidir. Kardiyovasküler sağlık ve hastalıkta, intestinal mikrobiyotanın etkisinin mevcut araştırmalara ek prospektif çalışmalar iledesteklenmesi ve farkındalığının artırılması, sağlığın ve hastalıklardan korunma stratejilerinin geliştirilmesinde önemlibir adım olacaktır. Yapılacak çalışmalarla intestinal mikrobiyotanın düzenlenmesinde, KVH’ye ilişkin geliştirilen stratejilerinin kullanılması ile risk altında olan bireylerin KVH’den korunmasının mümkün olacağı ve kardiyovasküler sağlığınsürdürülebileceği öngörülmektedir

Anahtar Kelime:

The Effect of Microbiota on Cardiovascular Health and Disease

Öz:

Recent studies have focused the effect of intestinal microbiota on individuals, since intestinal microbiota has an impact on human health and disease, and is associated with many diseases, including cardiovascular diseases (CVD). CVD are an important group of diseases with a high incidence and can result in death. 31% of the deaths in the world are due to CVD and it is estimated that this value will reach 41% after a decade. Studies have shown that immune system, inflammation process, endothelial damage and vascular changes affect intestinal microbiota and as a result many CVD and metabolic diseases develop. This situation has developed the idea that the diseases can be detected and prevented by examining and regulating intestinal microbiota. The most important role in protecting individuals from diseases and developing and sustaining health belongs to nurses. Nurses should increase their knowledge of current approaches, know the basic structure and functions of microbial communities and be able to reflect their knowledge and skills to their care. In cardiovascular health and disease, supporting and increasing awareness of the impact of intestinal microbiota for with the additional prospective studies will be an important step in the development of health and disease prevention strategies. In the regulation of intestinal microbiota with the studies to be done, it is predicted that, with theuse of strategies developed for CVD in individuals with risk, can be protected from CVD and that cardiovascular health can be sustained.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res 2017;120:1183–96.
2. T.C. Sağlık Bakanlığı. Türkiye Kalp Ve Damar Hastalıkları Önleme Ve Kontrol Programı Eylem Planı 2015-2020. Ankara, 2015.
3. WHO. World Heart Day. Available at: http://www.who.int/cardiovascular_diseases/world-heart-day/en/. Accessed May 9, 2019.
4. Altuntaş Y, Batman A. Microbiota and metabolic syndrome. [Article in Turkish]. Turk Kardiyol Dern Ars 2017;45:286–96.
5. Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. Curr Cardiol Rep 2015;17:120.
6. Sarkar S, Das B, Banerjee SK. Insights into the human gut microbiome and cardiovascular diseases. J Pract Cardiovasc Sci 2018;4:10–4.
7. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787–803.
8. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science 2016;352:560–4.
9. von Martels JZH, Sadaghian Sadabad M, Bourgonje AR, Blokzijl T, Dijkstra G, Faber KN, et al. The role of gut microbiota in health and disease: In vitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe 2017;44:3–12.
10. Berbers RM, Nierkens S, van Laar JM, Bogaert D, Leavis HL. Microbial Dysbiosis in Common Variable Immune Deficiencies: Evidence, Causes, and Consequences. Trends Immunol 2017;38:206–16.
11. Patterson E, Ryan PM, Cryan JF, Dinan TG, Ross RP, Fitzgerald GF, et al. Gut microbiota, obesity and diabetes. Postgrad Med J 2016;92:286–300.
12. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 2011;108 Suppl 1:4592–8.
13. Graf D, Di Cagno R, Fåk F, Flint HJ, Nyman M, Saarela M, et al. Contribution of diet to the composition of the human gut microbiota. Microb Ecol Health Dis 2015;26:26164.
14. Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, et al. Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB. J Am Heart Assoc. 2016 Feb 22 [E-pub ahead of print], doi: 10.1161/JAHA.115.002767.
15. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J 2014;35:904–10.
16. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575–84.
17. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013;4:1829.
18. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017;5:14.
19. Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation 2017;135:964–77.
20. Sharkey KA, Savidge TC. Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Auton Neurosci 2014;181:94–106.
21. Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, et al. Hypertension-Linked Pathophysiological Alterations in the Gut. Circ Res 2017;120:312–23.
22. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011;108:3047–52.
23. Kitai T, Kirsop J, Tang WH. Exploring the Microbiome in Heart Failure. Curr Heart Fail Rep 2016;13:103–9.
24. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838–42.
25. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014;64:1908–14.
26. TDK. İlaç ve Eczacılık Terimleri Sözlüğü. 2nd edition. Ankara, 2015.
27. Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin North Am 2012;41:781–803.
28. McElroy KG, Chung SY, Regan M. CE: Health and the Human Microbiome: A Primer for Nurses. Am J Nurs 2017;117:24–30.
29. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al.; American Heart Association StatisticsCommittee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American HeartAssociation. Circulation 2015;131:e29–322.
30. Patience S. Advising patients on nutrition and healthy eating. Br J Nurs 2016;25:1182–6.
31. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011;10:365–76.
32. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014;114:1852–66.
33. Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring) 2012;20:738–47.
34. Świątecka D, Narbad A, Ridgway KP, Kostyra H. The study on the impact of glycated pea proteins on human intestinal bacteria. Int J Food Microbiol 2011;145:267–72.
35. Hentges DJ, Maier BR, Burton GC, Flynn MA, Tsutakawa RK. Effect of a high-beef diet on the fecal bacterial flora of humans. Cancer Res 1977;37:568–71.
36. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al.; ANR MicroObes consortium. Dietary intervention impact on gut microbial gene richness. Nature 2013;500:585–8.
37. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576–85.
38. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559–63.
39. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011;334:105–8.
40. Fava F, Gitau R, Griffin BA, Gibson GR, Tuohy KM, Lovegrove JA. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes (Lond) 2013;37:216–23.
41. Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. Cell Metab 2015;22:658–68.
42. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008;3:213–23.
43. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009;1:6ra14.
44. Turnbaugh PJ. Microbes and Diet-Induced Obesity: Fast, Cheap, and Out of Control. Cell Host Microbe 2017;21:278–81.
45. Çakır İ, Çakmakçı LM. Probiyotikler: Tanımı, Etki Mekanizması, Seçim ve Güvenirlik Kriterleri. Gıda 2004;29:427–34.46. Karahan ZC, Güvener E. Probiyotikler. Flora 1999;4:156–62.
47. Khan MW, Kale AA, Bere P, Vajjala S, Gounaris E, Pakanati KC. Microbes, intestinal inflammation and probiotics. Expert Rev Gastroenterol Hepatol 2012;6:81–94.
48. Gionchetti P, Lammers KM, Rizzello F, Campieri M. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. Gastroenterol Clin North Am 2005;34:499–513.
49. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014;64:897–903.
50. Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M. Meta-Analysis: Effects of Probiotic Supplementation on Lipid Profiles in Normal to Mildly Hypercholesterolemic Individuals. PLoS One 2015;10:e0139795.
51. Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012;7:e45425.
52. Chan YK, El-Nezami H, Chen Y, Kinnunen K, Kirjavainen PV. Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(-/-) mice. AMB Express 2016;6:61.
53. Gómez-Guzmán M, Toral M, Romero M, Jiménez R, Galindo P, Sánchez M, et al. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res 2015;59:2326–36.
54. Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, et al. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut 2018;67:271–283.
55. Liu F, Prabhakar M, Ju J, Long H, Zhou HW. Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr 2017;71:9–20.
56. Cosola C, De Angelis M, Rocchetti MT, Montemurno E, Maranzano V, Dalfino G, et al. Beta-Glucans Supplementation Associates with Reduction in P-Cresyl Sulfate Levels and Improved Endothelial Vascular Reactivity in Healthy Individuals. PLoS One 2017;12:e0169635.
57. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012;590:447–58.
58. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854–9.
59. Çelebi G, Uygun A. İntestinal Mikrobiyota ve Fekal Transplantasyon. Güncel Gastroentoloji 2013;17:153–6.
60. Demirci H, Uygun A. Fekal Transplantasyon Nasıl ve Kime Uygulanmalı? Güncel Gastroentoloji 2014;18:444–7.
61. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al.; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044–9.
62. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014;48:693–702.
63. Landy J, Al-Hassi HO, McLaughlin SD, Walker AW, Ciclitira PJ, Nicholls RJ, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011;34:409–15.
64. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013;29:79–84.

APA	SERT M, Ozer Z (2019). Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. , 25 - 32. 10.5543/khd.2019.88700
Chicago	SERT MEDIHA,Ozer Zeynep Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. (2019): 25 - 32. 10.5543/khd.2019.88700
MLA	SERT MEDIHA,Ozer Zeynep Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. , 2019, ss.25 - 32. 10.5543/khd.2019.88700
AMA	SERT M,Ozer Z Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. . 2019; 25 - 32. 10.5543/khd.2019.88700
Vancouver	SERT M,Ozer Z Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. . 2019; 25 - 32. 10.5543/khd.2019.88700
IEEE	SERT M,Ozer Z "Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi." , ss.25 - 32, 2019. 10.5543/khd.2019.88700
ISNAD	SERT, MEDIHA - Ozer, Zeynep. "Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi". (2019), 25-32. https://doi.org/10.5543/khd.2019.88700

APA	SERT M, Ozer Z (2019). Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. Kardiyovasküler Hemşirelik Dergisi, 10(21), 25 - 32. 10.5543/khd.2019.88700
Chicago	SERT MEDIHA,Ozer Zeynep Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. Kardiyovasküler Hemşirelik Dergisi 10, no.21 (2019): 25 - 32. 10.5543/khd.2019.88700
MLA	SERT MEDIHA,Ozer Zeynep Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. Kardiyovasküler Hemşirelik Dergisi, vol.10, no.21, 2019, ss.25 - 32. 10.5543/khd.2019.88700
AMA	SERT M,Ozer Z Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. Kardiyovasküler Hemşirelik Dergisi. 2019; 10(21): 25 - 32. 10.5543/khd.2019.88700
Vancouver	SERT M,Ozer Z Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi. Kardiyovasküler Hemşirelik Dergisi. 2019; 10(21): 25 - 32. 10.5543/khd.2019.88700
IEEE	SERT M,Ozer Z "Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi." Kardiyovasküler Hemşirelik Dergisi, 10, ss.25 - 32, 2019. 10.5543/khd.2019.88700
ISNAD	SERT, MEDIHA - Ozer, Zeynep. "Kardiyovasküler Sağlık ve Hastalıkta Mikrobiyotanın Etkisi". Kardiyovasküler Hemşirelik Dergisi 10/21 (2019), 25-32. https://doi.org/10.5543/khd.2019.88700